Scholarlink

Purpose <p>We examined temporal trends in NSAID use among patients referred for evaluation of suspected coronary artery disease (CAD).</p> Methods <p>We conducted a drug utilisation study using population-based healthcare data from Western Denmark, covering 3.3&#xa0;million inhabitants. Three cohorts were categorised based on first-time diagnostic procedure for CAD assessment: coronary computed tomography angiography (CCTA; 2008–2022, <i>n</i> = 91,230), myocardial perfusion imaging (MPI; 2016–2022, <i>n</i> = 17,044), and all invasive coronary angiograms (ICA; 2008–2022, <i>n</i> = 128,327). We calculated the one-year prevalence proportion of NSAID use after the diagnostic procedures, stratified by procedure-defined CAD severity.</p> Results <p>NSAID use declined over the study period, regardless of CAD severity in patients undergoing CCTA or ICA (<i>p</i> &lt; 0.001). In 2021, the one-year prevalence of NSAID use was 17% among patients with severe CAD vs. 24% among patients without CAD diagnosed using CCTA (prevalence proportion ratio [PPR] 0.73, 95% confidence interval [CI]: 0.60–0.90). In patients undergoing MPI, 9% of those with severe CAD vs. 15% of those with no CAD used NSAIDs (PPR 0.58, 95% CI: 0.45–0.73). In patients undergoing ICA, 10% of those with severe CAD and 20% of those with no CAD used NSAIDs (PPR 0.53, 95% CI: 0.44–0.62).</p> Conclusion <p>Although NSAID use among patients with CAD has decreased and is lower than among patients without CAD, it remains relatively high in those with severe CAD.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-steroidal anti-inflammatory drug use in patients with varying severity of coronary artery disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Anne Bech-Drewes,
  • Kasper Bonnesen,
  • Morten Böttcher,
  • Jacob Hartmann Søby,
  • Simon Winther,
  • Lars Pedersen,
  • Henrik Toft Sørensen,
  • Timothy L. Lash,
  • Morten Schmidt

摘要

Purpose

We examined temporal trends in NSAID use among patients referred for evaluation of suspected coronary artery disease (CAD).

Methods

We conducted a drug utilisation study using population-based healthcare data from Western Denmark, covering 3.3 million inhabitants. Three cohorts were categorised based on first-time diagnostic procedure for CAD assessment: coronary computed tomography angiography (CCTA; 2008–2022, n = 91,230), myocardial perfusion imaging (MPI; 2016–2022, n = 17,044), and all invasive coronary angiograms (ICA; 2008–2022, n = 128,327). We calculated the one-year prevalence proportion of NSAID use after the diagnostic procedures, stratified by procedure-defined CAD severity.

Results

NSAID use declined over the study period, regardless of CAD severity in patients undergoing CCTA or ICA (p < 0.001). In 2021, the one-year prevalence of NSAID use was 17% among patients with severe CAD vs. 24% among patients without CAD diagnosed using CCTA (prevalence proportion ratio [PPR] 0.73, 95% confidence interval [CI]: 0.60–0.90). In patients undergoing MPI, 9% of those with severe CAD vs. 15% of those with no CAD used NSAIDs (PPR 0.58, 95% CI: 0.45–0.73). In patients undergoing ICA, 10% of those with severe CAD and 20% of those with no CAD used NSAIDs (PPR 0.53, 95% CI: 0.44–0.62).

Conclusion

Although NSAID use among patients with CAD has decreased and is lower than among patients without CAD, it remains relatively high in those with severe CAD.

Graphical abstract